BioVersys AG (SIX: BIOV), a Swiss biopharmaceutical company developing novel antibacterial drugs against multi-drug resistant (MDR) bacteria, announced today that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The event, scheduled for September 14-16, 2026 in New York City, provides a platform for the company to update investors on its clinical-stage pipeline.
Chief Financial Officer Hernan Levett will deliver a live presentation on September 16, 2026, from 12:30 to 1:00 PM ET at the Lotte New York Palace. In addition, Chief Executive Officer Dr. Marc Gitzinger will present a pre-recorded on-demand session available from September 11, 2026, with a replay accessible for 90 days via the H.C. Wainwright platform or the BioVersys website under the investor section.
This presentation comes at a critical time for the antimicrobial field. The rise of MDR bacteria poses a severe threat to global health, with the World Health Organization listing antimicrobial resistance as one of the top ten public health threats. BioVersys is addressing this urgent need with two proprietary technology platforms: TRIC and Ansamycin Chemistry. These platforms aim to overcome resistance mechanisms, block virulence production, and directly target bacterial pathogenesis, offering new treatment options for infections and microbiome-related chronic inflammatory diseases.
The company's lead programs target two major pathogens. BV100 is in Phase 3 for nosocomial infections caused by Acinetobacter baumannii, a notorious hospital-acquired pathogen with high mortality rates. Alpibectir, in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France, is in Phase 2 for tuberculosis, a disease that still kills over a million people each year. These programs highlight BioVersys's commitment to tackling both acute and chronic infections.
The H.C. Wainwright conference is known for attracting institutional investors, analysts, and industry leaders. BioVersys's participation offers a chance to highlight its progress and future milestones. The company has previously completed a listing on the SIX Swiss Exchange, indicating its maturity as a publicly traded entity. By presenting at this conference, BioVersys aims to increase its visibility among U.S. and global investors, potentially facilitating partnerships or funding for its late-stage trials.
Attendees can request one-on-one meetings with BioVersys's CEO and CFO through H.C. Wainwright representatives, allowing for deeper discussions on corporate strategy and pipeline development. The conference presentation will likely cover recent data from clinical trials, regulatory pathways, and the commercial potential of its products if approved.
BioVersys's focus on difficult-to-treat infections is particularly relevant given the recent surge in antibiotic-resistant cases and the limited number of new antibiotics in development. The company's innovative approaches, such as using ansamycin chemistry to inhibit bacterial virulence, differentiate it from traditional antibiotic development. This could lead to therapies that are less prone to resistance development, a key advantage in the long-term fight against MDR bacteria.
As the conference approaches, the investment community will be watching for any updates on BioVersys's Phase 3 trial for BV100 and Phase 2 for alpibectir. Positive results could position the company as a leader in the antimicrobial space and address a significant unmet medical need. The on-demand presentation ensures that even those unable to attend live can access the information, broadening the reach of BioVersys's message.
In summary, BioVersys's participation at the H.C. Wainwright conference underscores its commitment to advancing treatments for MDR infections and engaging with the financial community. The presentations by key executives will provide insights into the company's strategy and the potential impact of its pipeline on global health.
